Move to topTop
July 05, 2018

TOKYO, JAPAN - July 5, 2018 - Terumo Corporation (TSE: 4543) today announced that it has entered into an exclusive distribution relationship in Japan for a fentanyl injection anesthesia product with Piramal Critical Care Ltd., a wholly owned subsidiary of Piramal Enterprises Ltd., which is a diversified conglomerate headquartered in India. Piramal Critical Care acquired the product from Janssen Pharmaceutica NV in October 2016 and the product is currently marketed as a generic drug in Japan by Janssen Pharmaceutical K.K. With the conclusion of the exclusive distribution rights agreement, Terumo will take over marketing authorization of the product in Japan. The transfer of business is scheduled for the fiscal year 2019.

Fentanyl is a prescription-only narcotic analgesic that is widely used for postoperative pain management. Having designated pain management as an important business domain, Terumo also markets products that alleviate cancer pain and an intravenous injection of acetaminophen. With the conclusion of this exclusive distribution rights agreement, Terumo aims to expand treatment options to help alleviate patients' pain.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.